FDA withheld data from advisory committee

Share this article:
The FDA withheld from an advisory committee data linking the anti-obesity drug orlistat to a potential cancer risk before the committee recommended its switch from prescription to OTC status, alleges an article in the Cancer Letter. It said FDA had been aware of the data since 1997.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions